Cmp Dev Llc Company Profile

What is the competitive landscape for CMP DEV LLC

CMP DEV LLC has seven approved drugs.

There are thirty-three US patents protecting CMP DEV LLC drugs.

Summary for Cmp Dev Llc

US Patents:	33
Tradenames:	7
Ingredients:	7
NDAs:	7

Drugs and US Patents for Cmp Dev Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	9,757,394		Y
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	11,389,461		Y
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	10,660,907		Y
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	11,491,166		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,666,576		Y
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	12,226,528		Y

International Patents for Cmp Dev Llc Drugs

Country	Patent Number	Estimated Expiration
Japan	2021509114
World Intellectual Property Organization (WIPO)	2019130052
Morocco	50320
World Intellectual Property Organization (WIPO)	2019130052
World Intellectual Property Organization (WIPO)	2017075463
European Patent Office	3368045

Supplementary Protection Certificates for Cmp Dev Llc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0740668	PA2003001,C0740668	Lithuania		PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
0740668	03C0017	France		PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
1499331	SPC/GB13/034	United Kingdom		PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
2101777	201640021	Slovenia		PRODUCT NAME: AMBRISENTAN IN COMBINATION WITH TADALAFIL; NATIONAL AUTHORISATION NUMBER: EU/1/08/451/001-004; DATE OF NATIONAL AUTHORISATION: 20151120; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2059246	CR 2024 00050	Denmark		PRODUCT NAME: KOMBINATION AF (A) MACITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG (B) TADALAFIL ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1859 20240930
2059246	C02059246/01	Switzerland		PRODUCT NAME: MACITENTAN UND TADALAFIL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69446 10.10.2024

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cmp Dev Llc
• Cmp Pharma Inc

Last updated: July 29, 2026

CMP DEV LLC Competitive Landscape Analysis: Market Position, Strengths & Strategic Insights

CMP DEV LLC’s competitive posture in branded and generic pharmaceutical development is defined by where its programs sit in the value chain: early R&D and CMC execution versus late-stage clinical/regulatory execution and monetization through licensing, settlements, or ANDA launches. The firm’s market impact is best evaluated by mapping (1) its pipeline stage and therapeutic focus, (2) whether it plays offense through Para IV filings or defense through exclusivity-protected commercialization, and (3) how its manufacturing and regulatory credibility affects customer or partner allocation decisions.

No complete, source-backed dataset is available in the prompt to identify CMP DEV LLC’s specific drug targets, portfolio companies, FDA submissions, Orange Book listings, Para IV litigation, settlements, registered facilities, or revenue/contract references. Under the operating constraints, producing an accurate competitive landscape with patent-expiration dates, litigation status, or product-level launch risk is not possible.

CMP DEV LLC market position

Featured snippet answer: Without verified program and regulatory identifiers, CMP DEV LLC’s market position cannot be quantified against specific competing drugs, competitors, or geographic commercialization.

What strengths does CMP DEV LLC bring to pharmaceutical development?

Featured snippet answer: Strengths depend on the firm’s actual portfolio execution (CMC performance, filing throughput, regulatory outcomes, and enforcement outcomes). No portfolio specifics are provided in the input.

Which competitive threats does CMP DEV LLC face in pharma?

Featured snippet answer: Competitive threats are typically defined by (1) faster generic challengers, (2) stronger CMC-ready competitors for difficult formulations, (3) patent estate durability of originators, and (4) customer preference for sponsors with established FDA track records. These require program-level mapping that is not present.

How does CMP DEV LLC compare with peers by stage and therapeutic focus?

Featured snippet answer: Stage and therapeutic focus comparisons require known pipeline candidates, indicated uses, dosage forms, and regulatory pathway details.

Which partnerships matter most to CMP DEV LLC’s growth strategy?

Featured snippet answer: Partnership strength is measurable only through documented collaboration agreements, sponsored filings, co-development sponsors, or license/supply agreements tied to specific assets.

---

Key Takeaways

• CMP DEV LLC’s competitive landscape cannot be rendered with required patent, regulatory, litigation, or market-position specificity from the provided prompt.
• A business-grade competitive analysis requires program-level identifiers (assets, sponsors, FDA submissions, and patent listings). Those are not supplied.

---

FAQs

1. How do Para IV filing strategies typically change a developer’s competitive position?
2. What metrics best compare CMC capability across generic developers?
3. How should investors evaluate a sponsor’s likelihood of successful ANDA approval?
4. What drives customer selection for co-development or licensing partnerships in pharma?
5. How do patent estate strength and formulation complexity affect generic launch timing?

---

References

No sources were provided or extractable from the prompt.